Relative efficacy of antilipemic agents in non–high-density lipoprotein cholesterol reduction.

about

Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.

P2860

Q36197709-F74BDB03-8262-4F4D-8972-A24135369110

P2860

Relative efficacy of antilipemic agents in non–high-density lipoprotein cholesterol reduction.

Item

http://www.wikidata.org/entity/Q38007038

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Relative efficacy of antilipem ...... protein cholesterol reduction.

@en

type

Item

label

Relative efficacy of antilipem ...... protein cholesterol reduction.

@en

prefLabel

Relative efficacy of antilipem ...... protein cholesterol reduction.

@en

P1476

Relative efficacy of antilipem ...... protein cholesterol reduction.

@en

P2093

Cameron Lindsey

http://www.w3.org/2001/XMLSchema#string

Heather Pace

http://www.w3.org/2001/XMLSchema#string

Jennifer Santee

http://www.w3.org/2001/XMLSchema#string

P2860

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin.

Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial.

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.

Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia.

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

Impact of ezetimibe on atherosclerosis: is the jury still out?

Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.

Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy.

Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.

P304

447-456

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0897190012442722

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22551562

http://www.w3.org/2001/XMLSchema#string

P921

lipoprotein

HDL cholesterol

Relative efficacy of antilipemic agents in non–high-density lipoprotein cholesterol reduction.

about

P2860

P2860

Relative efficacy of antilipemic agents in non–high-density lipoprotein cholesterol reduction.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921